Stephens & Co. Reiterates Overweight on Codexis, Maintains $5 Price Target
Codexis, Inc. Q3 2026 Earnings Call Summary
Codexis (CDXS) Q3 2026 Earnings Call Transcript
Codexis Inc (CDXS) (Q3 2026) Earnings Call Highlights: Revenue Surges 124% as ECO Synthesis ...
What Codexis (CDXS) Said on Its Q3 Earnings Call
Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates
Codexis: Q3 Earnings Snapshot
Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
Codexis Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $19.262M Beat $18.720M Estimate
Codexis Affirms FY2026 Sales Guidance of $72.000M-$76.000M vs $73.882M Est
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
Codexis to Report Third Quarter 2026 Financial Results on November 12
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform
Codexis to Participate in Cantor Global Healthcare Conference 2026
Codexis (CDXS) Q2 2026 Earnings Call Transcript
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ...
Codexis, Inc. Q2 2026 Earnings Call Summary
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.